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S U M M A R Y
Objective: Clostridium tertium is considered an uncommon pathogen in humans, but is a cause of
bacteremia in patients with underlying hematological malignancies and neutropenia. A case series
highlighting 10 years of experience with C. tertium as a cause of bacteremia in this population is
presented; the cases were seen at a National Cancer Institute designated cancer center.
Methods: Institutional review board approval was obtained prior to the start of the study. All cases of C.
tertium bacteremia seen at H. Lee Mofﬁtt Cancer Center and Research Institute from 2005 to 2015 were
reviewed. The study population was identiﬁed by positive blood cultures obtained from the
microbiology laboratory over the same time period.
Results: Seven patients were found to have had C. tertium bacteremia. These patients had a temperature
of >38.3 8C at the time of diagnosis and severe neutropenia. All patients had a history of hematological
malignancy, ﬁve having acute myeloid leukemia and two having myelodysplastic syndrome. All of the
patients’ blood cultures cleared within 3 days of antibiotic therapy.
Conclusions: The unusual susceptibility pattern of C. tertium, with resistance to beta-lactams and
clindamycin, likely explains its presence in immunosuppressed patients. Vancomycin remains the drug
of choice. The pathogen continues to have a low virulence and a low mortality when treated
appropriately.
 2016 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Clostridium species are a diverse group of anaerobic, Gram-
positive, endospore-forming bacilli known to cause botulism,
tetanus, gas gangrene, and necrotic enteritis in humans. Clostridi-
um tertium is a non-exotoxin-producing, aerotolerant species that
is considered an uncommon pathogen in humans.1 C. tertium was
initially isolated by Herbert Henry from war wounds in 1917, and
was recognized as a human pathogen when cases of bacteremia
were reported in 1963.2,3 This bacterium is found in soil, animal
and human gastrointestinal tracts, and the commensal ﬂora of the
oral cavity. Infections with C. tertium have been described in
the literature with various clinical presentations, including
enterocolitis, septicemia, pneumonia and empyema, spontaneous* Corresponding author. Tel.: +1 646 691 5170.
E-mail address: Sowmya.Nanjappa@Mofﬁtt.org (S. Nanjappa).
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).peritonitis, abdominal and cutaneous abscesses, meningitis, gas
gangrene, and septic arthritis.1,4,5
A case series of C. tertium bacteremia in patients with
underlying hematological malignancies is presented. This series
represents a 10-year experience at a National Cancer Institute
designated cancer center, and the aim was to share this experience
of C. tertium as a true cause of clinical infection in cancer patients.
2. Materials and methods
Institutional review board approval was obtained prior to the
start of the study. In an effort to further study C. tertium
bacteremia, all cases of C. tertium bacteremia that occurred at H.
Lee Mofﬁtt Cancer Center and Research Institute from April 10,
2005 to April 8, 2015 were reviewed. The study population was
identiﬁed by positive blood cultures obtained from the microbiol-
ogy laboratory over the same time period. All culture results were
identiﬁed by the microbiology laboratory at the Mofﬁtt Cancerciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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clinical, and bacteriological data, including sex, age, underlying
disease and history of chemotherapy, symptoms, absolute
neutrophil count (ANC), antibiotic therapy, and clinical outcome.
Neutropenia was deﬁned as an ANC of <0.5  109/l. Neutropenic
fever was deﬁned as a patient with neutropenia and a one-time
fever of 38.3 8C or a fever of 38 8C sustained for more than 1 h.
The identiﬁcation of microorganisms was performed using
standard microbiological methods. The patient’s blood was
inoculated into a bioMe´rieux BacT/Alert standard aerobic bottle
and standard anaerobic bottle. Once the anaerobic bottle was
ﬂagged as being positive by the instrument, it was Gram-stained.
The bottle was then subcultured onto a blood, chocolate, and CDC
anaerobic agar plate. Once the anaerobic plate showed growth of
an anaerobic Gram-positive rod, an IDS Rapid ANA II identiﬁcation
panel was set up for identiﬁcation as C. tertium. anaerobic
susceptibilities are performed at the hospital.
2.1. Case presentation
Please refer to the following link to review a detailed
presentation of the cases: https://sites.google.com/site/
clostridiumtertium/.
3. Results
Seven patients were found to have had C. tertium bacteremia
between April 2005 and 2015 at the cancer institution, all of whom
were neutropenic. Interestingly, six patients (85%) had received
CLAG-M chemotherapy (cladribine, cytarabine, ﬁlgrastim, and
mitoxantrone) within 7–14 days before the onset of C. tertium
bacteremia. All seven patients (100%) had a temperature of
38.3 8F at the time when C. tertium bacteremia was diagnosed, as
well as severe neutropenia with an ANC of <0.2  109/l. All
patients had a history of hematological malignancy, ﬁve having
acute myeloid leukemia and two having myelodysplastic syn-
drome. Four patients had gastrointestinal symptoms including
diarrhea, nausea, vomiting, and abdominal pain; two patients had
respiratory symptoms including dyspnea and hypoxia; one patient
remained asymptomatic. Two patients had computed tomography
scans of the abdomen performed; none of them identiﬁed the
potential source of infection and none of them demonstrated
colitis despite the presence of gastrointestinal symptoms. Blood
cultures from three patients were polymicrobial with Enterococcus
species. All of the patients’ blood cultures cleared within 3 days of
antibiotic therapy. Five patients died within 4 months after the
isolation of C. tertium (Table 1).Table 1
Clinical summary of seven patients with Clostridium tertium bacteremia
Patient Sex/age
(years)
Underlying disease Source of
infection
Days with positive
C. tertium blood
cultures
Isolate
to C. te
1 F/82 Acute myeloid
leukemia
Abdomen 3 None 
2 F/36 Acute myeloid
leukemia
Abdomen 1 None 
3 F/42 Acute myeloid
leukemia
Unknown 2 None 
4 M/55 Myelodysplastic
syndrome
Abdomen 3 Entero
5 M/60 Acute myeloid
leukemia
Unknown 2 Entero
6 M/69 Myelodysplastic
syndrome
Unknown 2 Entero
7 M/60 Acute myeloid
leukemia
Unknown 2 None 
F, female; M, male.4. Discussion
Clostridium species account for 0.5–2% of all clinically
signiﬁcant bacteremia, with Clostridium perfringens being the
most common isolate. C. tertium is the second most common
Clostridium bacteremia at the study institution after C.
perfringens and has been seen as a cause of true clinical
infection especially over the last 2 years. C. tertium has been
traditionally considered non-pathogenic.6–8 It is now increas-
ingly reported as a human pathogen, having a strong association
with septicemia in patients with neutropenia and hematological
malignancies.
Unlike other Clostridium species, C. tertium does not produce
exotoxins; therefore the pathogenesis of infection is not well
understood. It has been postulated that compromise of the
intestinal mucosa heightens the risk of C. tertium translocation
into the systemic circulation.1,9 Additionally, chemotherapy agents
can lead to inﬂammation and abrasion of the intestinal mucosa,
which may explain why patients with a hematological malignancy
who are undergoing chemotherapy have an increased susceptibil-
ity to infection.4
Common characteristics of C. tertium infection included fever
and generalized gastrointestinal complaints such as abdominal
pain, diarrhea, rectal bleeding, and nausea. However, in some
cases, patients with C. tertium infection were completely asymp-
tomatic. Additionally, most patients were neutropenic without a
deﬁned source of infection.
It can be difﬁcult for laboratories to correctly identify C. tertium
isolates, as it is aerotolerant and can grow weakly under aerobic
conditions. Due to this, C. tertium is often confused with Bacillus
species, although C. tertium is catalase-negative and only produces
spores under anaerobic conditions, while Bacillus species are
catalase-positive and produce spores under aerobic conditions.6,9–
11 This may cause delays in treatment or patients may receive
incorrect antibiotic therapy.10
C. tertium has been shown to be sensitive to ﬂuoroquinolones,
imipenem, vancomycin, and trimethoprim–sulfamethoxazole, and
resistant to other beta-lactams and clindamycin. C. tertium isolates
can either be sensitive or resistant to metronidazole.4,10 C. tertium
is mostly resistant to broad-spectrum cephalosporins, and given
the difﬁculty in identifying C. tertium isolates, empiric therapeutic
strategies may fail in hospitalized patients with sepsis.6,10,12
Therefore, standard therapeutic regimens for the treatment of
septicemia may be inadequate for C. tertium. There is limited
literature regarding the duration of antibiotic therapy, although it
is believed that approximately 15 to 27 days of treatment is
sufﬁcient.9s in addition
rtium
Antibiotics received Survived
Vancomycin, piperacillin–tazobactam,
ciproﬂoxacin
No
Vancomycin, piperacillin–tazobactam,
metronidazole, clindamycin
No
Piperacillin–tazobactam, clindamycin Yes
coccus faecium Cefepime, vancomycin, piperacillin–tazobactam No
coccus faecium Vancomycin, metronidazole No
coccus gallinarum Cefepime, vancomycin, piperacillin–tazobactam No
Ciproﬂoxacin, cefepime, vancomycin Yes
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exotoxin-producing bacterium, unlike Clostridium septicum and C.
perfringens, which are subgroups of the Clostridium species known
to cause spontaneous and traumatic myonecrosis, respective-
ly.3,13,14 Bacteremia with C. septicum and C. perfringens can lead to
systemic toxicity and septic shock, with a mortality rate greater
than 60%, secondary to the toxins produced by these species.8,15,16
Therefore, it is not entirely clear from the literature whether C.
tertium is a true pathogen or merely a contaminant. Additionally, C.
tertium has been isolated from polymicrobial blood cultures,
making the signiﬁcance of C. tertium bacteremia further indis-
tinct.6,9
Most patients with C. tertium bacteremia have been neutrope-
nic due to chemotherapy, without a deﬁned source of infection.17 A
literature review demonstrated a summary of 42 cases with C.
tertium bacteremia, of which 38 patients were neutropenic from
chemotherapy. In these cases, patients developed C. tertium
bacteremia within several days after becoming neutropenic.12
However, there have been rare cases of C. tertium bacteremia in
non-neutropenic patients, such as patients with end-stage liver
disease from chronic alcohol use, systemic lupus erythematosus on
high-dose steroids, and inﬂammatory bowel disease. Despite the
low pathogenic potential of C. tertium species, effective treatment
should not be delayed.9
Although C. tertium is rare with low virulence, it appears to be a
cause of true clinical infection in neutropenic patients.6 Of the
cases presented, all patients with monomicrobial bacteremia had a
high-grade fever and symptoms that resolved after the initiation of
appropriate antibiotic therapy,17 demonstrating that C. tertium
bacteremia does cause clinical disease. Nevertheless, the mortality
related to C. tertium bacteremia that is treated appropriately seems
to be low. In patients with neutropenia, especially when there is
evidence of gastrointestinal involvement,11 clinicians should be
encouraged to consider C. tertium when Gram-positive rods are
found in blood culture, and to initiate appropriate antimicrobial
therapy such as vancomycin.
In conclusion, C. tertium bacteremia is a rare pathogen in
neutropenic patients. It is often mistaken for Bacillus species, which
may cause delays in treatment. Although uncommon, the presence
of C. tertium bacteremia should prompt a high suspicion for
disruption to the gastrointestinal tract mucosa. In all of the cases
reported at this cancer institution, blood cultures cleared with
antibiotic therapy; no patient died as a result of C. tertiumbacteremia. Therefore, the pathogen continues to have a low
virulence and a low mortality when treated appropriately. C.
tertium is known to be a true pathogen in patients with underlying
hematological malignancies and neutropenia. It is hoped that this
case series will assist clinicians when encountering this pathogen
as a true cause of clinical infection.
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